André Muller
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
André C.
Muller is currently Chairman at Chiron Investments AG.
The current roles also include Independent Director at Cellectis SA starting in 2025, Director at Idorsia Ltd. starting in 2026, and Director positions at Idorsia Pharmaceuticals US, Inc. and Idorsia (Shanghai) Pharmaceuticals Co., Ltd. Former roles include Chief Executive Officer at Idorsia Ltd. and Idorsia Pharmaceuticals Ltd. from 2024 to 2025, Independent Director at Carmat SA from 2020 to 2024, Director at Nxera Pharma Japan Co., Ltd., Chief Financial Officer & Executive Vice President at Actelion Ltd. from 2013 to 2017, and Chief Financial Officer at Pierre Fabre SA from 1994 to 2011.
Education includes an MBA from EM Lyon Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IDORSIA LTD. -.--% | 31.12.2024 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTIS S.A. | Direktor/Vorstandsmitglied | 26.06.2025 |
| IDORSIA LTD | Direktor/Vorstandsmitglied | 06.05.2026 |
Chiron Investments AG | Vorsitzender | - |
Idorsia Pharmaceuticals US, Inc. | Direktor/Vorstandsmitglied | - |
Idorsia (Shanghai) Pharmaceuticals Co., Ltd. | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| IDORSIA LTD | Vorstandsvorsitzender | 01.07.2025 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals | Vorstandsvorsitzender | 01.07.2025 |
| CARMAT SA | Direktor/Vorstandsmitglied | 25.06.2024 |
| ACTELION | Finanzdirektor/CFO | 01.01.2017 |
| ░░░░░░ ░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Actelion Ltd.
Actelion Ltd. Pharmaceuticals: MajorHealth Technology Develops, produces and markets pharmaceutical drugs | Health Technology |
Pierre Fabre SA
Pierre Fabre SA BiotechnologyHealth Technology Engages in research and preclinical development of biologics & pharmaceuticals | Health Technology |
Cellectis SA
Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
EM Lyon Business School
EM Lyon Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmat SA
Carmat SA Medical SpecialtiesHealth Technology Specializes in the construction of artificial hearts | Health Technology |
Idorsia Ltd.
Idorsia Ltd. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of medicines for unmet medical needs | Health Technology |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals | Health Technology |
Idorsia Pharmaceuticals US, Inc. | Health Technology |
Idorsia (Shanghai) Pharmaceuticals Co., Ltd. | |
Idorsia Pharmaceuticals Japan Ltd.
Idorsia Pharmaceuticals Japan Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells daridorexants | Health Technology |
Chiron Investments AG |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen